Barclays analyst Etzer Darout initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $47 price target
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Synopsys downgraded, Oracle upgraded: Wall Street’s top analyst calls
- Janux Therapeutics initiated with a Buy at Truist
- Buy Rating for Janux Therapeutics Inc: Promising Oncology Innovations and Strategic Advancements
- Janux Therapeutics resumed with a Buy at Stifel
- Janux Therapeutics initiated with a Buy at Guggenheim